Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 2/20 | 0.30 |
| ▸ | F10 | P00742 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13203688 | 0.93 | GCK (0.36) | GCKLMNAHPGDALDH1A1KMT2A | |
| SCHEMBL13221618 | 0.92 | PIK3CD (0.31) | LMNAHPGD | |
| SCHEMBL2963435 | 0.91 | ALDH1A1 (0.34) | GCKLMNAHPGDALDH1A1KMT2A | |
| SCHEMBL13348495 | 0.90 | — | — | |
| SCHEMBL2661967 | 0.89 | SLC8A1 (0.35) | GCKLMNAHPGDALDH1A1 | |
| SCHEMBL3499096 | 0.88 | LMNA (0.31) | LMNAHPGDALDH1A1 | |
| SCHEMBL2660665 | 0.88 | ALDH1A1 (0.40) | GCKLMNAHPGDALDH1A1KMT2A | |
| SCHEMBL2968240 | 0.86 | ALDH1A1 (0.34) | LMNAHPGDALDH1A1KMT2AHTT | |
| SCHEMBL2660368 | 0.85 | ALDH1A1 (0.44) | GCKLMNAHPGDALDH1A1KMT2A | |
| SCHEMBL2659452 | 0.85 | HPGD (0.37) | LMNAHPGDALDH1A1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508524-A2 | Indole compound | Takeda Pharmaceutical Company Limited (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-7777047-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20100137610-A1 | Indole compound | YASUMA TSUNEO | 2010-06-03 | — | — | US | disclosed |
| US-7718798-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718798-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7652133-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090286975-A1 | Indole compound | YASUMA TSUNEO | 2009-11-19 | — | — | US | disclosed |
| US-20080096877-A1 | Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137610-A1 | Indole compound | GCKR, GPR119, SLC5A1 | GCK 4/4885LMNA 4727/4885HPGD 1786/4885 |
| US-20090286975-A1 | Indole compound | GCKR, GPR119, SLC5A1 | GCK 4/4885LMNA 4727/4885HPGD 1786/4885 |
| US-20080096877-A1 | Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example | GCKR, GCK, KHK | GCK 2/4885LMNA 4653/4885HPGD 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.